Introduction
Fabry disease (OMIM #301500) is a rare, inherited, lysosomal, genetic storage disease caused by mutations in the GLA gene on the X chromosome, which results in a lack or significant deficiency of the lysosomal enzyme α-galactosidase A (α-GAL A). This deficiency leads to the accumulation of glycosphingolipids (mainly globotriaosylceramide and its deacylated form globotriaosylsphingosine [lyso-GL-3]) in many cells of the body, and to the development of multisystem complications that impair the quality of life and lead to premature death (Table 1 ) [1] .
The clinical picture of Fabry disease is very diverse and depends on the α-GAL A activity.
A complete lack of or trace α-GAL A activity (<5%) causes the classic form of the disease, which mainly affects male patients. People with partially preserved enzymatic activity develop the nonclassical late-onset form of Fabry disease. The onset and severity of symptoms in women are primarily dependent on the random pattern of inactivation of one of the two X chromosomes [2, 3] .
The first symptom of the classic form of the disease, already seen in early childhood, is chronic or paroxysmal neuropathic pain in the hands and feet, defined as acroparesthesia.
Later, other symptoms associated with thin nerve fiber involvement occur, such as impaired perspiration (hypohidrosis, anhidrosis), abdominal pain, and diarrhea. Characteristic symptoms of the classic form also include angiokeratoma-type cutaneous lesions and corneal opacities (cornea verticillata) [1] . Even in childhood, clinically silent proteinuric chronic kidney disease may occur with microalbuminuria or glomerulosclerosis. Multiorgan symptoms of the classic form of Fabry disease usually appear in young adults and may include chronic kidney disease, left ventricular hypertrophy, myocardial fibrosis, arrhythmias and conduction abnormalities, transient ischemic attacks, and strokes. People with late-onset Fabry disease typically have cardiac symptoms, a stroke, or chronic kidney disease in the fourth or fifth decade of life [1] . The classic form of Fabry disease is an early-onset multisystem disease that typically presents with cornea verticillata and angiokeratomas. In contrast, the non-classic form has a later onset and usually affects a single organ, most often the heart; angiokeratomas or cornea verticillata are usually not found.
The intensity of cell and organ changes progresses in the course of Fabry disease. Metabolite accumulation begins as early as in the fetal period, leading to the involvement of many tissues and severe organ dysfunction ( Fig. 1 ) [4] . The life expectancy of men with Fabry disease is shorter by 15-20 years, and that of women by 6-10 years, in relation to the average life expectancy in the population [5] . It should be emphasized that even in the stage of late complications, the diagnosis of Fabry disease is difficult. Chronic kidney disease, and cardiac and neurological symptoms are very common in the general population and are usually caused by common civilization diseases.
The estimated prevalence of Fabry disease in the general world population is 1/100,000. The prevalence of Fabry disease reported in Polish studies is 2.5/100,000 in the entire population: 1/40,000 in men and 0.85/100,000 (1/117,000) in women [6] [7] [8] . In men, the prevalence of the classic mutations, which result in no detectable α-GAL A activity, is about 1 in 20,000 to 45,000. The prevalence of the non-classic mutations, with some α-GAL A activity, is about 10 times greater. In women, the prevalence of mutations is higher than in men (2:1 ratio) because Fabry disease is inherited with the X chromosome.
In Poland, there have been no guidelines for the diagnosis and management of Fabry's disease [9] . The position statement was prepared by an interdisciplinary group of experts and approved by the Boards of the Polish Cardiac Society, the Polish Society of Inborn Errors of Metabolism, the Polish Society of Internal Medicine, the Polish Society of Nephrology, and the Polish Society of Neurology. Although disease-specific treatments for Fabry disease include other treatments than ERT (e.g. migalast), only ERT is currently reimbursed in Poland. This position paper aims to provide practical recommendations for physicians who treat patients with Fabry disease in Poland and therefore it concentrates on ERT.
Diagnosis of Fabry disease
Due to the lack of specific symptoms indicative of Fabry disease, the diagnostic process is difficult and can last for many years. The diagnosis of Fabry disease requires the simultaneous consideration of the clinical picture and the results of enzymatic, biochemical, and genetic tests [10, 11] . Most of the symptoms of Fabry disease, including hypertrophic cardiomyopathy, proteinuric chronic kidney disease, and ischemic stroke, are nonspecific and have a wide differential diagnosis. The identification of certain symptoms such as cornea verticillata in a slit lamp or the histopathological confirmation of angiokeratoma is of greater diagnostic significance [10, 11] .
To diagnose the disease, α-GAL A activity is measured in whole blood (dried blood spot method), plasma, or leukocytes. An activity of <5%, usually found in men with the classic form of the disease or in homozygous women, definitely indicates Fabry disease. Testing for α-Gal A activity alone is diagnostic in men only. In women, α-Gal A activity may be normal or only slightly decreased; therefore, a disease-causing mutation in the GLA gene must be found to diagnose the disease. Genetic testing should be offered to men as well to determine disease form, enable family screening, and rule our benign polymorphisms associated with reduced α-Gal A activity (Table 2) [11] . Additional diagnostic information to assess the pathogenicity of mutations (variants of unknown significance) and disease severity (in heterozygous women) can be obtained by the determination of the disease biomarkers (especially plasma lyso-GL-3). Detection of GL-3 deposits in histopathological examination (of heart, kidneys, skin) indicates Fabry disease, but should be interpreted together with clinical, biochemical, and genetic data.
Renal complications
Chronic kidney disease is a serious and frequent complication of Fabry disease. In the asymptomatic period, histopathological examination may indicate the accumulation of glycosphingolipids in kidney cells, including podocytes and cells of the endothelium, mesangium, and renal tubules. Deposits of glycosphingolipids in the kidneys are present as early as in the fetal period [12, 13] . Further progression of the disease leads to interstitial fibrosis, glomerulosclerosis, and renal tubular atrophy. These changes cause albuminuria and proteinuria and progressive reduction of glomerular filtration followed by renal failure until end-stage, requiring dialysis or renal transplantation [11] .
The stage of chronic kidney disease in Fabry disease should be assessed based on the glomerular filtration rate (GFR) and the severity of albuminuria /proteinuria. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is recommended to estimate glomerular filtration [14] . In children, GFR should be determined with nuclear techniques before deciding on treatment. A kidney biopsy may help in the case of diagnostic doubts and in the evaluation of the effectiveness of enzyme replacement therapy. The assessment and treatment of chronic kidney disease in adult patients with Fabry disease should follow the general KDIGO 2012 recommendations [14] .
Cardiac complications
Cardiac complications of Fabry disease are frequent, affect about 40-60% of patients, both men and women, and are a significant cause of premature mortality [15] [16] [17] [18] [19] [20] . The accumulation of glycosphingolipids in cardiomyocytes, ischemic lesions associated with the involvement of small vessels, and inflammation contribute to the concentric hypertrophy of the left ventricle and subsequent fibrosis. Hypertrophy of the left ventricle, observed in about 50% of men and 30% of women, is most often diagnosed from the third decade of life [16] .
With the progression of the disease, irreversible changes occur, including fibrosis [21] .
Cardiac hypertrophy can be assessed with an electrocardiogram (ECG), echocardiography, and magnetic resonance imaging (MRI) of the heart, and myocardial fibrosis of the left ventricle can be assessed by late gadolinium enhancement (LGE) in MRI. The earliest cardiac manifestation of Fabry disease is the initial shortening, followed by the prolongation of the PR interval, bradycardia, progressive atrioventricular and intraventricular conduction disorders, and cardiac hypertrophy. Many patients develop chronic heart failure, with a preserved ejection fraction that decreases with the progression of the disease. Angina is frequently reported in patients with Fabry disease. Usually epicardial coronary arteries are normal, but perfusion defects and slow coronary flow can be found on angiography and on myocardial perfusion tomography. Endomyocardial biopsy shows lumen narrowing of intramyocardial arteries due to hypertrophy and hyperplasia of smooth muscle and endothelial cells, and increased fibrosis of the intimal and medial layer [22] and changes in the morphology of the heart valves resulting in regurgitation are also frequent complications of Fabry disease [22, 23] . In addition, myocardial fibrosis increases the risk of life-threatening arrhythmias. The use of cardiac magnetic resonance native T1 mapping allows assessment of myocardial involvement before left ventricle hypertrophy. The incidence of clinically significant ventricular arrhythmias is low, but there is relatively high incidence of bradycardia and need for pacing [24] . It is suspected that sudden cardiac death in Fabry disease is related to bradycardia [24] .
After the diagnosis of Fabry disease, 24-48-hour Holter ECG monitoring is recommended [24] . Early detection of cardiac arrhythmias and conduction disorders allows for the introduction of appropriate treatment in some cases, such as cardiac pacing or cardioverter-defibrillator implantation, or antithrombotic treatment in atrial fibrillation. Some forms of arrhythmias may also be treated with radiofrequency ablation. The mechanisms involved in injury to the central nervous system are not well understood, but changes in cerebral vessels and cardiac embolism are thought to contribute to ischemic changes in the brain [28] . Fabry disease increases the risk of ischemic stroke (4.2-fold in the population of stroke patients aged 35-45 years), which usually occurs before the age of 50 years. [29] . Stroke can be both ischemic and hemorrhagic. Ischemic stroke is most often found in the vertebrobasilar region; the "pulvinar" sign (hyperintense signal in the T1 MRI sequence) and enlargement of the basilar artery are sometimes observed. The distribution of ischemic lesions (white matter hyperintensities associated with small vessel disease) may be similar to those seen in multiple sclerosis or hypertensive encephalopathy [30] . Involvement of large vessels is usually secondary to heart disease (cardiogenic strokes). Early-onset stroke in the absence of other causes, as well as co-existing renal and cardiac disease with burning pains in the feet and hands in anamnesis, should lead to the diagnostic procedures for Fabry disease. Fabry disease is also associated with neuropsychiatric problems like depression and cognitive decline; therefore, antidepressants may be helpful as symptomatic therapy. [31] 
Neurological complications

High-risk populations
Published studies and guidelines indicate the need to perform diagnostic testing for Fabry disease in patients with illnesses or symptoms that are classic and frequent complications of this disease (Table 3 ) [28, [32] [33] [34] [35] [36] .
Family screening and genetic counseling
When a diagnosis of Fabry disease has been made, it is crucial to do a clinical and genetic screening of the patient's family members. Typically, such screening reveals Fabry disease in several family members, who can benefit from early diagnosis and treatment. The diagnosis of Fabry disease causes much distress and raises many questions among patients and their families. Thus, genetic counseling provided by a geneticist with expertise in Fabry disease must be offered to explain the X-linked pattern of inheritance and the available diagnostic and management options. Apart from the information on the medical aspects of the disease, patients should receive psychological support when needed. Information on the methods of prenatal diagnosis should be given to patients who plan to have children [11] 
Enzyme replacement therapy in Fabry disease
International standards and guidelines unequivocally accept the use of enzyme replacement therapy (ERT) as an optimal and specific treatment method for patients with confirmed Fabry disease, which stops the progression of organ changes and stabilizes or improves organ function (Table 4 ) [11, 37] . Studies have confirmed the beneficial effect of ERT on both the removal of GL-3 deposits from organs and the severity of the disease on biochemical evaluation (GL-3, lyso-GL-3 in plasma). The effect on intermediate endpoints, including albuminuria or proteinuria, estimated glomerular filtration rate, the mass of the left ventricle, and the severity of pain, has also been confirmed [38, 39] . In addition, ERT (agalsidase beta) led to significant reductions in the clinically significant composite renal/cardiac/neurological endpoint (-61%, p=0.034, for the "per-protocol" population) [40, 41] .
Numerous clinical observations also indicate the dependence of the clinical effects on the stage of the disease in which ERT was initiated. The use of ERT in patients at a younger age, with less severe organ changes, without irreversible complications, or without previous serious cardiovascular events, resulted in more beneficial clinical effects [40, [42] [43] [44] [45] [46] . [47, 48] . There have been no direct comparative studies assessing the long-term impact of these therapies on significant clinical parameters in a sufficiently large group of patients with a homogeneous phenotype. However, available observations indicate a relationship between the therapeutic effect and the dose of ERT (nine-fold higher intracellular concentration of agalsidase beta as compared to agalsidase alfa). This dependence is confirmed by the results of comparative assessments and studies in which agalsidase alfa was switched to agalsidase beta or vice versa [49] [50] [51] [52] .
The most commonly reported adverse reactions associated with ERT were post-infusion reactions (more frequent with agalsidase beta). Most of the reactions were mild to moderate, were not a reason for discontinuation of therapy, and subsided with subsequent administrations. To minimize their severity, it is possible to reduce the rate of ERT administration and give pre-medication with antihistamines, analgesics, and/or corticosteroids. ERT cannot be used simultaneously with chloroquine, amiodarone, benzoquinone, or gentamycin because these substances potentially inhibit the activity of intracellular α-GAL A [47, 48] .
Since 2016, the oral drug migalastat (Galafold, Amicus) has also been registered for use in the treatment of Fabry disease. Migalastat is a pharmacological chaperone that works by stabilizing the mutated forms of α-GAL A and increasing their availability in lysosomes.
Migalastat is indicated for the treatment of adults and adolescents from 16 years of age, but only in patients with a mutation that makes them sensitive to its action [53] .
Indications for starting and stopping enzyme replacement therapy and contraindications
As already mentioned, early enzyme replacement is crucial to suppress the progression of [11] . Moreover, in patients with VUS, a geneticist with expertise in Fabry disease should give advice on the pathogenicity of a given VUS.
In the opinion of the authors of this position statement, in the context of Polish clinical practice, appropriate look at the indications for starting ERT was presented in the Canadian Fabry Initiative Group guidelines published in 2017 [52] ; they are the basis for the clinical recommendations for starting and stopping ERT, as well as its contraindications, presented in Table 5 .
Symptomatic treatment
In For GFR 60-90 ml/min/1.73 m 2 , CKD grade 2: at least 3 concordant estimates or GFR measurements for at least 6 months with a slope of the GFR curve greater than the age-related norm For GFR>135 ml/min /1.73 m 2 : a 15% decrease in GFR or a GFR curve slope greater than the age-related norm measured by nuclear medicine techniques. The estimated GFR is not precise in this respect and therefore cannot be used. Elsevier Inc.) [4] 
